Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.65USD
16 Aug 2018
Change (% chg)

$0.00 (+0.03%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.64
Volume
38,315
Avg. Vol
71,966
52-wk High
$3.30
52-wk Low
$0.47

Chart for

About

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary... (more)

Overall

Beta: --
Market Cap(Mil.): $55.04
Shares Outstanding(Mil.): 35.51
Dividend: --
Yield (%): --

Financials

  BLPH.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.39 -- --
ROI: -187.88 1.78 14.61
ROE: -359.90 3.28 16.33

BRIEF-Bellerophon Therapeutics Q1 Shr Loss $0.04

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

10 May 2018

BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse

* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

08 May 2018

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

15 Mar 2018

Earnings vs. Estimates